Arcutis Biotherapeutics(ARQT) - 2025 Q1 - Quarterly Results

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update Westlake Village, CA, May 6, 2025 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial- stage biopharmaceutical company focused on developing meaningful innovations in immuno- dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update. "In the first quarter we again delivered excellent performance driven by strong demand growth for our ZORYVE portfolio, which of ...